7.3 Weight Management & Metabolic Health in Survivorship

7.3 Weight Management & Metabolic Health in Survivorship

Quick Summary: While malnutrition and involuntary weight loss dominate acute cancer treatment phases, post-treatment weight gain and adverse body composition modifications represent major clinical challenges during survivorship. Unintended weight gain during and after curative cancer therapy is particularly prevalent among survivors of breast cancer, prostate cancer, and pediatric malignancies. Rather than reflecting healthy tissue repletion, post-treatment weight gain predominantly consists of visceral adipose tissue accumulation accompanied by skeletal muscle loss—a phenotype known as sarcopenic obesity.

---

1. Population-Specific Weight & Metabolic Dynamics

A. Breast Cancer Survivors

Between 50% and 70% of women diagnosed with stage I-III breast cancer experience significant weight gain ($\ge 5\%$ to $10\%$ of baseline body weight) during and after adjuvant therapy.

Etiological Factors:

1. Chemotherapy-Induced Ovarian Failure (CIOF): Cytotoxic regimens (e.g., cyclophosphamide, doxorubicin, paclitaxel) trigger abrupt premature menopause, causing rapid drops in circulating $17\beta$-estradiol, reductions in resting energy expenditure (REE), and shifts toward central visceral fat storage.
2. Adjuvant Endocrine Therapies:
   • Aromatase Inhibitors (AIs: Anastrozole, Letrozole, Exemestane): Suppress peripheral estrogen synthesis in postmenopausal women, inducing arthralgias (joint stiffness/pain) that impair physical activity and worsen sarcopenia.
   • Selective Estrogen Receptor Modulators (SERMs: Tamoxifen): Alter lipid metabolism and increase hepatic steatosis risk.
3. Corticosteroid Co-medications: High-dose dexamethasone given as an antiemetic during chemotherapy stimulates appetite, fluid retention, and hyperinsulinemia.

Chemotherapy / Endocrine Therapy
       │
       ├──> Ovarian Failure & Estrogen Loss ──> Decreased REE & Visceral Adiposity
       ├──> Joint Arthralgias (AIs)        ──> Reduced Physical Activity
       └──> Corticosteroids                ──> Hyperinsulinemia & Appetite Stimulation

B. Prostate Cancer Survivors on Androgen Deprivation Therapy (ADT)

Androgen Deprivation Therapy (ADT)—using GnRH agonists (leuprolide, goserelin), GnRH antagonists (relugolix, degarelix), or antiandrogens (enzalutamide, abiraterone)—is a cornerstone treatment for prostate cancer. However, severe testosterone suppression ($<50\text{ ng/dL}$) induces profound adverse body composition shifts within 3 to 12 months:

• Lean Muscle Depletion: 2% to 4% loss of total skeletal muscle mass within 1 year.
• Visceral Fat Expansion: 10% to 15% increase in total fat mass and up to 20% expansion of abdominal visceral fat.
• Metabolic Syndrome Triad: Rapid onset of severe insulin resistance, hypertriglyceridemia, and hypertension.
• Cardiovascular Mortality: ADT doubles the risk of developing incident type 2 diabetes and significantly increases cardiovascular event mortality.

C. Pediatric Cancer Survivors

Survivors of pediatric acute lymphoblastic leukemia (ALL) and central nervous system (CNS) tumors frequently display severe early-onset obesity and metabolic syndrome.

• Cranial Radiation Toxicity: Radiation doses to the hypothalamic-pituitary region ($>18-24\text{ Gy}$) cause growth hormone deficiency (GHD) and disrupt hypothalamic leptin/satiety signaling, leading to hyperphagia and rapid weight gain.
• Glucocorticoid Maintenance: Long-term pulse dexamethasone or prednisone therapy impairs bone mineral density and alters adipocyte differentiation.

---

2. Pathophysiology of Sarcopenic Obesity

Sarcopenic obesity represents the confluence of two adverse body composition extremes: sarcopenia (low muscle mass and muscle strength) and obesity (high body fat percentage, particularly visceral fat).

+-----------------------------------------------------------------------------------+
|                         PATHOPHYSIOLOGY OF SARCOPENIC OBESITY                     |
+-----------------------------------------------------------------------------------+
|                                 CANCER THERAPIES                                  |
|               (Chemotherapy, Radiation, ADT, Endocrine Suppression)              |
+-----------------------------------------+-----------------------------------------+
                                          |
                 +------------------------+------------------------+
                 |                                                 |
                 v                                                 v
       CATABOLIC MUSCLE LOSS                            VISCEROLYTIC FAT GAIN
  - Pro-inflammatory Cytokines                     - Increased Visceral Adipose
    (TNF-alpha, IL-6, IL-1beta)                    - Hyperinsulinemia & Insulin Resistance
  - Elevated Myostatin Gene Expression             - Increased Leptin / Decreased Adiponectin
  - Intramyocellular Lipid (Steatosis)             - Ectopic Lipid Deposition in Muscle
                 |                                                 |
                 +------------------------+------------------------+
                                          |
                                          v
                             SARCOPENIC OBESITY PHENOTYPE
                 - Severe Functional & Strength Decline
                 - Elevated Cancer Recurrence & Cardiovascular Mortality

Clinical Diagnostics for Sarcopenic Obesity:

• Body Mass Index (BMI) Limitations: BMI often fails to detect sarcopenic obesity because lost muscle mass is mathematically masked by gained fat mass, keeping body weight stable despite severe internal metabolic deterioration.
• Body Composition Assessment: Dual-energy X-ray Absorptiometry (DXA) or Bioelectrical Impedance Analysis (BIA) reveals a low Appendicular Lean Mass Index (ALMI) ($<7.0\text{ kg/m}^2$ in men, $<5.5\text{ kg/m}^2$ in women) combined with high percent body fat ($>25\%$ in men, $>35\%$ in women).

---

3. Evidence-Based Clinical Management Strategies

Managing weight gain and metabolic syndrome in cancer survivors requires a delicate balance: promoting energy deficit to reduce visceral fat while providing adequate protein and stimulus to preserve or build skeletal muscle.

A. Nutritional Interventions

B. Exercise Interventions: The Dual-Modality Model

Nutrition alone cannot reverse sarcopenic obesity during caloric restriction; targeted exercise is mandatory.

1. Progressive Resistance Training (PRT):
   • Frequency: 2 to 3 days per week non-consecutive.
   • Intensity: 60% to 80% of 1-Repetition Maximum (1RM); 2 to 3 sets of 8 to 12 repetitions targeting major muscle groups (chest, back, quadriceps, hamstrings, shoulders).
   • Impact: Upregulates muscle protein synthesis, downregulates myostatin, and preserves muscle cross-sectional area during weight loss.
2. Aerobic Exercise:
   • Frequency: 150+ minutes per week of moderate-intensity activity.
   • Impact: Increases mitochondrial density, enhances fatty acid oxidation, and improves cardiorespiratory fitness ($VO_2\text{ peak}$).

---

4. Managing Cardiovascular Risk & Insulin Resistance

Cardiovascular disease (CVD) is now the leading cause of non-cancer death among long-term survivors of breast and prostate cancer. Targeted monitoring and clinical intervention for metabolic risk factors are essential components of oncology nutrition practice:

+-----------------------------------------------------------------------------------+
|                 METABOLIC SYNDROME CLINICAL MONITORING TARGETS                     |
+-----------------------+-----------------------+-----------------------------------+
| Clinical Metric       | Target Threshold      | Recommended Intervention          |
+-----------------------+-----------------------+-----------------------------------+
| Fasting Blood Glucose | < 100 mg/dL           | Low Glycemic Load Diet + PRT      |
| Hemoglobin A1c        | < 5.7%                | Fiber >= 30g/day; Weight Loss     |
| Triglycerides         | < 150 mg/dL           | Omega-3 Fatty Acids; Limit Sugars |
| HDL Cholesterol       | > 40 mg/dL (men)      | Aerobic Exercise; Healthy Fats    |
|                       | > 50 mg/dL (women)    |                                   |
| Blood Pressure        | < 120/80 mmHg         | DASH Diet Pattern; Sodium <2000mg |
| Waist Circumference   | < 40 inches (men)     | 300-500 kcal Energy Deficit       |
|                       | < 35 inches (women)   |                                   |
+-----------------------+-----------------------+-----------------------------------+